Literature DB >> 19192766

Clinical rationale for administering fentanyl to cancer pain patients: two Delphi surveys of pain management experts in Denmark.

Ramune Jacobsen1, Claus Møldrup, Lona Christrup.   

Abstract

OBJECTIVE: To describe the rationale behind the choice of fentanyl administration forms as reported by Danish nurses and physicians specializing in pain management.
METHODS: Sixty nurses and 60 physicians specializing in pain management in Denmark were contacted via an Internet survey system to perform two Delphi surveys. In the brainstorming phase, the main reasons for administering and not administering fentanyl patches and oral transmucosal fentanyl citrate (OTFC) were identified. In the second phase, the nursing and medical experts rated the importance of these reasons on an 11-point Numerical Rating Scale.
RESULTS: Responses from 10 pain nurses and 14 pain doctors were used for the final analysis. Impossible or difficult oral intake of analgesia was the most important reason to administer fenantyl patches, whereas patients' dermatological problems and neuropathic pain origin were the most important reasons for not administering fenantyl patches in both panels. OTFC was presented as an alternative or second choice administration form for breakthrough cancer pain by both nurses and doctors. A damaged mouth, the high cost, and energy required for administration of this medication were reported as the main reasons why OTFC was only rarely prescribed to cancer pain patients in Denmark.
CONCLUSIONS: The reasons for administering fentanyl in different administration forms reported by Danish pain nurses and pain specialists partly differed from those derived from the literature. Studies of pain management traditions could improve the understanding of the reasons for analgesic administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19192766     DOI: 10.5055/jom.2008.0042

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  4 in total

Review 1.  Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.

Authors:  Frank Elsner; Giovambattista Zeppetella; Josep Porta-Sales; Ignacio Tagarro
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations.

Authors:  Dörte Huscher; Lesley Ann Saketkoo; David Pittrow; Dinesh Khanna
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

3.  Comment on 'What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion'.

Authors:  Raffaele Giusti; Lucilla Verna; Daniela Iacono; Agnese Vannini; Corrado Ficorella; Giampiero Porzio
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

4.  Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study.

Authors:  J Boceta; A De la Torre; D Samper; M Farto; R Sánchez-de la Rosa
Journal:  Clin Transl Oncol       Date:  2016-11       Impact factor: 3.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.